Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.


Published on .

Wall Street greeted Kellogg Co.'s stock with a tepid response following the FDA's approval of a claim that its psyllium-based cereals "may reduce the risk of coronary heart disease."

Kellogg's statement that it would use the claim in ads for Bran Buds barely moved the ticker price.

The street's sanguine attitude might be due to the fact that the company already has been pouring many of its marketing dollars into health-related advertising.

Most Popular
In this article: